|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Bandim Health Project |
|---|---|
| Collaborators: |
Danish Council for Development Research Novo Nordisk Fonden til Lægevidenskabens Fremme Medical Research Council Laboratories, Gambia |
| Information provided by: | Bandim Health Project |
| ClinicalTrials.gov Identifier: | NCT00168571 |
Purpose
Few data exist on long-term persistence of measles antibodies after vaccination of West African infants. The data that do exist indicate that the antibody titres decline very rapidly. Our data would be the first to describe the persistence of measles antibodies after two doses of measles vaccine, and the study would allow us to identify unprotected children and offer them revaccination. Since persistence of measles antibodies is of crucial importance to measles control, the study will contribute significantly to the existing knowledge and might have important implications for future eradication programmes.
| Condition | Intervention | Phase |
|---|---|---|
|
Measles |
Biological: Measles vaccine |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Long-term Follow-up of Protective Measles Antibodies in the Two-dose Study of Standard-titre Measles Vaccine in Guinea-Bissau |
| Estimated Enrollment: | 1960 |
| Study Start Date: | March 2002 |
| Study Completion Date: | January 2007 |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 6 Years to 10 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria: Children participating in the Two-dose trial (Non-Specific Effects of Standard Titre Measles Vaccination, Protocol ID: IC18-CT95-0011-Twodose1)
Exclusion Criteria: Severe illness requiring hospitalisation
Contacts and Locations| Guinea-Bissau | |
| Bandim Health Project | |
| Bissau, Apartado 861, Guinea-Bissau, 1004 Bissau Codex | |
| Study Director: | PETER AABY, MSc, Dr Med | Bandim Health Project |
| Principal Investigator: | MAY-LILL GARLY, PHD, DTM&H | Bandim Health Project |
More Information
| ClinicalTrials.gov Identifier: | NCT00168571 History of Changes |
| Other Study ID Numbers: | LTAB-2288/2292-Twodose1, NOVO-2288, Lægevidenskabens Fremme-2292 |
| Study First Received: | September 9, 2005 |
| Last Updated: | September 21, 2011 |
| Health Authority: | Guinea-Bissau: Ministry of Health; Gambia: MRC Ethics Committee |
|
Measles vaccine Measles Measles antibodies Immunisation |
Low income country Guinea-Bissau Bandim Health Project Measles antibody level |
|
Measles Morbillivirus Infections Paramyxoviridae Infections Mononegavirales Infections RNA Virus Infections Virus Diseases |
Antibodies Immunoglobulins Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions |